Just months after Pfizer slashed hundreds of jobs in its own neuroscience R&D program, the pharmaceutical giant is making notable investments in two Boston-based neuroscience startups.
The company announced Wednesday that Tevard Biosciences and QurAlis will each receive one of Pfizer’s coveted “Golden Tickets”— a valuable voucher for the fees associated with renting a spot for one scientist for one year at LabCentral, a biotech incubator in Cambridge, Mass. For companies based elsewhere, the ticket also allows a startup to set up shop at the noted space in Kendall Square.
Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!
GET STARTEDWhat is it?
STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.
What's included?
- Daily reporting and analysis
- The most comprehensive industry coverage from a powerhouse team of reporters
- Subscriber-only newsletters
- Daily newsletters to brief you on the most important industry news of the day
- STAT+ Conversations
- Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
- Exclusive industry events
- Premium access to subscriber-only networking events around the country
- The best reporters in the industry
- The most trusted and well-connected newsroom in the health care industry
- And much more
- Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.
About the Author Reprints
